98%
921
2 minutes
20
Background: Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.
Objective: To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years.
Methods: We conducted a national cross sectional serosurvey from June 1, 2022, to August 31, 2022, in children aged 0-19 years undergoing an anesthetic procedure at eight tertiary pediatric hospitals. Participant questionnaires were administered, and blood samples tested using the Roche Elecsys Anti-SARS-CoV-2 total spike and nucleocapsid antibody assays. Spike and nucleocapsid seroprevalence adjusted for geographic and socioeconomic imbalances in the participant sample compared to the Australian population was estimated using multilevel regression and poststratification within a Bayesian framework.
Results: Blood was collected from 2,046 participants (median age: 6.6 years). The overall adjusted seroprevalence of spike-antibody was 92.1% (95% credible interval (CrI) 91.0-93.3%) and nucleocapsid-antibody was 67.0% (95% CrI 64.6-69.3). In unvaccinated children spike and nucleocapsid antibody seroprevalences were 84.2% (95% CrI 81.9-86.5) and 67.1% (95%CrI 64.0-69.8), respectively. Seroprevalence was similar across geographic remoteness index and socioeconomic quintiles. Nucleocapsid antibody seroprevalence increased with age while the point seroprevalence of the spike antibody seroprevalence decreased in the first year of life and then increased to 97.8 (95% Crl 96.1-99.2) by 12-15 years of age.
Conclusion: Most Australian children and adolescents aged 0-19 years, across all jurisdictions were infected with SARS-CoV-2 by August 2022, suggesting rapid and uniform spread across the population in a very short time period. High seropositivity in unvaccinated children informed COVID-19 vaccine recommendations in Australia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410239 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300555 | PLOS |
Alzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.
Environ Res
September 2025
School of Public Health, The University of Queensland, Brisbane, Australia; Queensland Alliance for Environmental Health Sciences, The University of Queensland, Brisbane, Australia. Electronic address:
Heat-Health Action Plans (HHAPs) are essential public health interventions to reduce heat-related mortality and morbidity, yet how heat-related health risks have changed following their implementation remains scarce. This study aimed to examine the temporal changes in heat-related mortality in relation to the implementation of the HHAPs across five major cities of Australia, including Melbourne, Sydney, Brisbane, Adelaide, and Perth. Daily mortality and temperature data from 1999-2019 were analysed using distributed lag non-linear models to compare the heat-related mortality attributable fractions (AF%) between pre- and post-HHAP periods.
View Article and Find Full Text PDFSci Rep
September 2025
Department of Neurosurgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Moorenstraße 5, 40225, Duesseldorf, Germany.
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition associated with high rates of morbidity and mortality, mainly due to post-hemorrhagic complications such as cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI). Recent evidence implicates platelet activation and inflammatory mediators in the cascade of secondary injury following aSAH. Monitoring and timely treatment of post-SAH complications is critical to improve clinical outcomes.
View Article and Find Full Text PDFOpen Heart
September 2025
Freeman Hospital Cardiothoracic Centre, Newcastle upon Tyne, UK
Background: Stroke volume is an established echocardiographic marker but has not been widely studied in patients with ST-segment elevation myocardial infarction (STEMI). We aimed to evaluate stroke volume in a cohort of uncomplicated anterior STEMI and to assess its prognostic role in those with severe left ventricle (LV) systolic dysfunction.
Methods And Results: This is a single-centre retrospective analysis of consecutive patients presenting with anterior STEMI who underwent uncomplicated primary percutaneous coronary intervention.
Front Public Health
September 2025
School of Public Health, University of Rwanda, Kigali, Rwanda.
Background: Female sex workers (FSWs) in sub-Saharan Africa bear a disproportionate burden of HIV acquisition. While pre-exposure prophylaxis (PrEP) is increasingly accessible in the region, limited data exist on FSWs awareness of and willingness to use PrEP. This study aimed to assess PrEP awareness and willingness to use it, along with associated factors, among FSWs in Kigali, Rwanda.
View Article and Find Full Text PDF